{"id":"NCT01431274","sponsor":"Boehringer Ingelheim","briefTitle":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2011-09-09","resultsPosted":"2015-07-16","lastUpdate":"2015-07-16"},"enrollment":2624,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DEVICE","name":"Respimat","otherNames":[]}],"arms":[{"label":"tiotropium+olodaterol low dose FDC","type":"EXPERIMENTAL"},{"label":"tiotropium+olodaterol high dose FDC","type":"EXPERIMENTAL"},{"label":"olodaterol","type":"ACTIVE_COMPARATOR"},{"label":"tiotropium low dose","type":"ACTIVE_COMPARATOR"},{"label":"tiotropium high dose","type":"ACTIVE_COMPARATOR"}],"summary":"The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).","primaryOutcome":{"measure":"Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.","timeFrame":"1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.","effectByArm":[{"arm":"Olodaterol (5 μg)","deltaMin":0.133,"sd":0.008},{"arm":"Tiotropium (2.5 μg)","deltaMin":0.148,"sd":0.008},{"arm":"Tiotropium (5 μg)","deltaMin":0.139,"sd":0.008},{"arm":"Tio+Olo FDC (2.5/5 μg)","deltaMin":0.241,"sd":0.008},{"arm":"Tio+Olo FDC (5/5 μg)","deltaMin":0.256,"sd":0.008}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG003 vs OG004","p":"0.2169"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.5849"},{"comp":"OG000 vs OG001","p":"0.1863"},{"comp":"OG001 vs OG002","p":"0.4352"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":239,"countries":["United States","Argentina","Australia","Bulgaria","Canada","China","Czechia","Denmark","Estonia","Finland","France","Germany","Guatemala","Hungary","India","Italy","Japan","Mexico","Netherlands","New Zealand","Portugal","Russia","Slovenia","South Korea","Turkey (Türkiye)"]},"refs":{"pmids":["33175291","32943047","32848380","32848379","32776202","32671684","32462607","30261995","29355547","27993292","26112656","25573406"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":528},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection"]}}